Astellas Pharma has terminated its collaboration with CytomX Therapeutics, ending a partnership valued at up to $1.7 billion focused on cancer immunotherapy development. The collaboration aimed to develop novel cancer treatments using CytomX's proprietary technology platform.
The partnership's difficulties became apparent in the first quarter of 2025, when Astellas chose not to continue IND enabling activities for the companies' initial collaboration target. Instead, the Japanese pharmaceutical company shifted focus to their second nominated collaboration target by initiating GLP toxicology studies for that molecule.
The termination represents a significant setback for CytomX, which had structured the deal as a major revenue opportunity. The collaboration was designed to leverage CytomX's Probody platform technology to develop next-generation cancer immunotherapies with improved safety and efficacy profiles.
The decision reflects broader industry challenges in cancer immunotherapy development, where high development costs and uncertain clinical outcomes continue to pressure pharmaceutical partnerships. For Astellas, the move allows reallocation of resources to other pipeline priorities as the company refines its oncology strategy.
The partnership's end highlights the volatility in biotech collaborations, where initial enthusiasm can quickly shift as companies reassess clinical and commercial prospects during early development phases.